Egyptian International Pharmaceutical Investments (CAI:PHAR) Change In Receivables : E£-613 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Change In Receivables?

Egyptian International Pharmaceutical Investments's change in receivables for the quarter that ended in Dec. 2023 was E£71 Mil. It means Egyptian International Pharmaceutical Investments's Accounts Receivable declined by E£71 Mil from Sep. 2023 to Dec. 2023 .

Egyptian International Pharmaceutical Investments's change in receivables for the fiscal year that ended in Dec. 2023 was E£-613 Mil. It means Egyptian International Pharmaceutical Investments's Accounts Receivable increased by E£613 Mil from Dec. 2022 to Dec. 2023 .

Egyptian International Pharmaceutical Investments's Accounts Receivable for the quarter that ended in Dec. 2023 was E£1,153 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Egyptian International Pharmaceutical Investments's Days Sales Outstanding for the three months ended in Dec. 2023 was 67.88.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Egyptian International Pharmaceutical Investments's liquidation value for the three months ended in Dec. 2023 was E£-3,056 Mil.

Egyptian International Pharmaceutical Investments Change In Receivables Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Change In Receivables Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-234.77

-567.80

-613.40

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-173.93	-251.71	-197.17	-235.66	71.15

Egyptian International Pharmaceutical Investments Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-613 Mil.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Egyptian International Pharmaceutical Investments's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1153.421	/	1550.576	*	91
=	67.88

2. In Ben Graham's calculation of liquidation value, Egyptian International Pharmaceutical Investments's accounts receivable are only considered to be worth 75% of book value:

Egyptian International Pharmaceutical Investments's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	675.798	-	5717.98	+	0.75 * 1153.421	+	0.5 * 2242.396
=	-3,056

Egyptian International Pharmaceutical Investments Change In Receivables Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.